These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6785360)

  • 41. Intravesical epirubicin treatment following TUR in superficial bladder tumours.
    Imamoğlu MA; Bakirtaş H; Yiğitbaşi O; Ersoy H; Sertçelik AN
    Arch Esp Urol; 2001 Dec; 54(10):1147-53. PubMed ID: 11852530
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Intravesical BCG therapy for superficial bladder cancer].
    Segawa N; Iwamoto Y; Azuma H; Yamamoto K; Ueda H; Katsuoka Y
    Hinyokika Kiyo; 1998 Sep; 44(9):627-31. PubMed ID: 9805666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Intravesical instillation of cytotoxic T-lymphocytes induced by soluble tumor antigen in the prophylaxis of recurrence of bladder cancer].
    Li X; Sun D; Gao W
    Zhonghua Wai Ke Za Zhi; 2001 Aug; 39(8):619-22. PubMed ID: 11758203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Drug prevention of recurrence in bladder tumors. Intravesical adriblastin instillation following transurethral resection of non-infiltrating bladder tumors].
    Maier U; Kuber W
    Fortschr Med; 1983 Mar; 101(12):535-40. PubMed ID: 6852720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Intravesical therapy: Influence on superficial bladder cancer recurrence].
    García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; González Alvarez RC; Jalón Monzón A; Martínez Gómez FJ; Sánchez Trilla A; Regadera Sejas J
    Arch Esp Urol; 2007; 60(1):36-43. PubMed ID: 17408170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal intravesical dosage of thio-tepa in the prophylaxis of recurrent bladder papillomatosis.
    Oravisto KJ
    Scand J Urol Nephrol; 1972; 6(1):26-8. PubMed ID: 4626940
    [No Abstract]   [Full Text] [Related]  

  • 47. The effects of intravesical instillation of Thio-Tepa on the recurrence rate of bladder tumors.
    Asahi T; Matsumura Y; Tanahashi T; Yoshimoto J; Kaneshige T; Fujita Y; Ohmori H
    Acta Med Okayama; 1980 Feb; 34(1):43-9. PubMed ID: 6446839
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Efficacy and safety of different dosages of intravesical epirubicin instillation for prevention of primary superficial bladder carcinoma from recurrence].
    Wu ZB; Lin GB; Chen BJ; Wu ZM; Rong RM
    Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):507-9. PubMed ID: 16188156
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Repeat transurethral resection lowers recurrence rates in T1 bladder tumors, even after intravesical mitomycin C.
    Oosterlinck W
    Nat Clin Pract Urol; 2006 Nov; 3(11):582-3. PubMed ID: 17088923
    [No Abstract]   [Full Text] [Related]  

  • 50. Rationale for intensive intravesical chemotherapy.
    Soloway MS
    Prog Clin Biol Res; 1984; 153():287-95. PubMed ID: 6433357
    [No Abstract]   [Full Text] [Related]  

  • 51. [Own experiences with the treatment of papillomatous bladder neoplasms by intracystic administration of Thio-Tepa].
    Dobrzecki W; Kaczmarek A
    Pol Przegl Chir; 1977 Jun; 49(6a):743-8. PubMed ID: 407554
    [No Abstract]   [Full Text] [Related]  

  • 52. Patient instructions for bladder installation of Thiotepa.
    Howe SM
    AUAA J; 1986; 6(3):6. PubMed ID: 2938564
    [No Abstract]   [Full Text] [Related]  

  • 53. [Whole bladder wall laser irradiation to prevent bladder cancer recurrence with intravesical HpD and ascorbic acid].
    Li C; Chen Y; Wang Q
    Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):463-5. PubMed ID: 10920885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
    Besarani D; Al-Akraa M
    BJU Int; 2006 Jul; 98(1):232-3. PubMed ID: 16831177
    [No Abstract]   [Full Text] [Related]  

  • 55. [Diacetyl-glucaro-(1 leads to 4) (6 leads to 3)-dilactone (SLA) for prevention of bladder tumor recurrence].
    Shiraishi T; Nihira H
    Hinyokika Kiyo; 1970 Oct; 16(10):586-92. PubMed ID: 5529995
    [No Abstract]   [Full Text] [Related]  

  • 56. [Clinical-experience with thiotepa in the treatment of bladder cancer].
    Gallo FJ; Menéndez-Ondina L; Matallana A; Bonilla JA; Serrano E; Carballido JA; Mendoza A
    Actas Urol Esp; 1978; 2(5):237-40. PubMed ID: 103371
    [No Abstract]   [Full Text] [Related]  

  • 57. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa.
    Prout GR; Koontz WW; Coombs LJ; Hawkins IR; Friedell GH
    J Urol; 1983 Oct; 130(4):677-80. PubMed ID: 6411939
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Postoperative prophylactic intravesical instillation of tetrahydropyranyl-adriamycin (THP) for superficial bladder cancer].
    Kanayama H; Yokota K; Kurokawa Y; Kagawa S; Yokozeki H; Inai T; Ogawa I; Akazawa S; Hashimoto H; Mizuta K
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):651-5. PubMed ID: 10234296
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Prophylaxis of superficial bladder cancer with 1 mg of intravesical BCG: comparison with other doses].
    Corti Ortíz D; Rivera Garay P; Avilés Jasse J; Hidalgo Carmona F; MacMillan Soto G; Coz Cañas LF; Vargas Delaunoy R; Susaeta Saénz de San Pedro R
    Actas Urol Esp; 1993 Apr; 17(4):239-42. PubMed ID: 8342413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.